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Supplemental Figure 1  One-Year Stroke Rates in Relation to Antithrombotic Guideline Adherence 
 
Panel A   Entire population (unselected study cohort)                                        
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Panel B   High-risk cohort (CHA2DS2-VASc ≥2) 
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Figure Legend 
Supplemental Figure 1  One-Year Stroke Rates in Relation to Antithrombotic Guideline Adherence 
Panel A   Entire population (unselected study cohort)                                        
Panel B   High-risk cohort (CHA2DS2-VASc ≥2) 
 
CHA2DS2-VASc = congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack (TIA), vascular 
disease, age 65-74 years, sex category (female); OAC = oral anticoagulant. 
Some percentages may not sum up to total due to rounding. 
 
